Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of CXA-101/tazobactam on QT/QTc Intervals in Healthy Subjects
NCT02508753Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2010
- Primary completion
- Jul 2010
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ceftolozane and tazobactam in bacterial infection (4 arms), sponsored by Merck & Co. Primary endpoints: Change from pre-dose baseline in the individual subject correction (QTcI) at Day 13 and Change from the periodic specific pre-dose baseline of QT/QTcI at Day 13. Started Jun 2010; status: completed.
02
Drugs
ceftolozanetazobactam
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT02508753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02508753.